# GT Medical Technologies, Inc.

> GT Medical Technologies is a Tempe, Arizona medical device company that developed GammaTile, an FDA-cleared bioresorbable radiation therapy implant for operable brain tumors. Founded by brain tumor specialists from the Barrow Neurological Institute, the company places collagen tiles embedded with Cesium-131 seeds directly into the tumor cavity at the time of surgery, delivering immediate, targeted radiation while sparing healthy tissue. Backed by a $100M Series E led by Viking Global Investors, GT Medical has treated more than 2,000 patients and is pursuing randomized trials to establish GammaTile as a standard of care.

- **Founded:** 2017
- **Headquarters:** Tempe, Arizona, United States
- **Founders:** David G. Brachman, MD, FASTRO (Co-Founder & Chief Technology Officer), Heyoung McBride, MD, MS, FASTRO (Co-Founder), Peter Nakaji, MD (Co-Founder), Emad Youssef, MD (Co-Founder (deceased)), Theresa Thomas, MS, CCRC (Co-Founder)
- **Team size:** ~120 employees
- **Products:** GammaTile Therapy, GammaTile Centers of Excellence Program
- **Notable:** GammaTile received FDA clearance in 2018 for recurrent brain tumors and in 2020 for newly diagnosed malignant tumors, Treated its 2,000th patient with GammaTile as of August 2025, ROADS randomized controlled trial showed GammaTile reduced 12-month surgical-bed recurrence to 1.3% vs 15.4% for standard care, with 24-month survival of 61.7% vs 35.7%

## Products & services

- **GammaTile Therapy** — An FDA-cleared, bioresorbable collagen tile embedded with Cesium-131 radioactive seeds, surgically implanted in the tumor cavity at the time of resection to deliver immediate, focused radiation to residual tumor cells while sparing healthy brain tissue.
- **GammaTile Centers of Excellence Program** — A designation program recognizing hospitals and brain tumor centers with demonstrated expertise in GammaTile implantation and multidisciplinary neuro-oncology care.

## Achievements

- GammaTile received FDA clearance in 2018 for recurrent brain tumors and in 2020 for newly diagnosed malignant tumors
- Treated its 2,000th patient with GammaTile as of August 2025
- ROADS randomized controlled trial showed GammaTile reduced 12-month surgical-bed recurrence to 1.3% vs 15.4% for standard care, with 24-month survival of 61.7% vs 35.7%
- Closed an oversubscribed $100M Series E led by Viking Global Investors in June 2026
- Raised approximately $246 million in total funding
- Launched the GammaTile Centers of Excellence program with USC Brain Tumor Center as first designee

## Latest updates

- **2026-06** — Completed an oversubscribed $100 million Series E financing led by Viking Global Investors to accelerate commercial expansion and the BRIDGES glioblastoma trial.
- **2026-05** — Released final data from the ROADS randomized controlled trial demonstrating statistical superiority of GammaTile over standard of care.
- **2025-08** — Reached the clinical milestone of 2,000 patients treated with GammaTile.
- **2025** — Launched the GammaTile Centers of Excellence program, designating USC Brain Tumor Center as the first center.

## Links

- Website: https://gtmedtech.com
- LinkedIn: http://www.linkedin.com/company/gt-medical-technologies-inc
- Twitter/X: https://twitter.com/gammatile
- Instagram: https://www.instagram.com/gammatile/
- Facebook: https://www.facebook.com/GammaTile/

---

Profile page: https://yespress.io/gt-medical-technologies-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-20